You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCilostazol
Accession NumberDB01166  (APRD00155)
TypeSmall Molecule
GroupsApproved
DescriptionCilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. [Wikipedia]
Structure
Thumb
Synonyms
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
Cilostazole
Cilostazolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pletaltablet100 mg/1oralOtsuka America Pharmaceutical, Inc.1999-01-15Not applicableUs
Pletaltablet50 mg/1oralOtsuka America Pharmaceutical, Inc.1999-01-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cilostazoltablet50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-06-26Not applicableUs
Cilostazoltablet100 mg/1oralGolden State Medical Supply, Inc.2006-09-06Not applicableUs
Cilostazoltablet50 mg/1oralCarilion Materials Management2005-05-17Not applicableUs
Cilostazoltablet50 mg/1oralRoxane Laboratories, Inc2005-05-17Not applicableUs
Cilostazoltablet100 mg/1oralBreckenridge Pharmaceutical, Inc.2009-09-28Not applicableUs
Cilostazoltablet100 mg/1oralbryant ranch prepack2004-11-23Not applicableUs
Cilostazoltablet100 mg/1oralBIOKEY INC.2014-04-012016-04-05Us
Cilostazoltablet50 mg/1oralGolden State Medical Supply, Inc.2011-10-18Not applicableUs
Cilostazoltablet50 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Cilostazoltablet50 mg/1oralEon Labs, Inc.2005-11-08Not applicableUs
Cilostazoltablet50 mg/1oralApotex Corp.2011-10-18Not applicableUs
Cilostazoltablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-23Not applicableUs
Cilostazoltablet100 mg/1oralPhysicians Total Care, Inc.2005-09-09Not applicableUs
Cilostazoltablet100 mg/1oralCarilion Materials Management2011-01-05Not applicableUs
Cilostazoltablet100 mg/1oralRoxane Laboratories, Inc2011-01-05Not applicableUs
Cilostazoltablet50 mg/1oralCorepharma LLC.2006-09-06Not applicableUs
Cilostazoltablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-18Not applicableUs
Cilostazoltablet100 mg/1oralGolden State Medical Supply, Inc.2011-10-18Not applicableUs
Cilostazoltablet100 mg/1oralEon Labs, Inc.2004-11-23Not applicableUs
Cilostazoltablet100 mg/1oralApotex Corp.2011-10-18Not applicableUs
Cilostazoltablet100 mg/1oralSTAT Rx USA LLC2006-09-06Not applicableUs
Cilostazoltablet100 mg/1oralCardinal Health2011-10-18Not applicableUs
Cilostazoltablet100 mg/1oralPreferred Pharmaceuticals, Inc.2014-07-28Not applicableUs
Cilostazoltablet100 mg/1oralTeva Pharmaceuticals USA Inc2012-10-24Not applicableUs
Cilostazoltablet100 mg/1oralCorepharma LLC.2006-09-06Not applicableUs
Cilostazoltablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-10-24Not applicableUs
Cilostazoltablet50 mg/1oralGolden State Medical Supply, Inc.2006-09-06Not applicableUs
Cilostazoltablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-23Not applicableUs
Cilostazoltablet50 mg/1oralbryant ranch prepack2005-05-17Not applicableUs
Cilostazoltablet50 mg/1oralBIOKEY INC.2014-04-012016-04-05Us
Cilostazoltablet50 mg/1oralCardinal Health2011-02-18Not applicableUs
Cilostazoltablet100 mg/1oralAvera Mc Kennan Hospital2015-04-01Not applicableUs
Cilostazoltablet50 mg/1oralTeva Pharmaceuticals USA Inc2012-04-24Not applicableUs
Cilostazoltablet50 mg/1oralAmerican Health Packaging2014-07-30Not applicableUs
Cilostazoltablet50 mg/1oralBreckenridge Pharmaceutical, Inc.2009-09-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PletaalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIN7Z035406B
CAS number73963-72-1
WeightAverage: 369.4607
Monoisotopic: 369.216475133
Chemical FormulaC20H27N5O2
InChI KeyInChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N
InChI
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
IUPAC Name
6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
SMILES
O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinolones and derivatives
Direct ParentHydroquinolones
Alternative Parents
Substituents
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Alkyl aryl ether
  • Benzenoid
  • Heteroaromatic compound
  • Tetrazole
  • Cyclic alcohol
  • Azole
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
PharmacodynamicsCilostazol is a quinolinone derivative indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs.
Mechanism of actionCilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
Related Articles
AbsorptionCilostazol is absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in Cmax and a 25% increase in AUC. Absolute bioavailability is not known.
Volume of distributionNot Available
Protein binding95-98%
Metabolism

Hepatic. Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine. Two metabolites are active, with one metabolite appearing to account for at least 50% of the pharmacologic (PDE III inhibition) activity after administration of cilostazol.

Route of eliminationCilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine. Cilostazol is eliminated predominately by metabolism and subsequent urinary excretion of metabolites. The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%). No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydro-cilostazol. About 30% of the dose was excreted in urine as 4'-trans-hydroxy-cilostazol.
Half life11-13 hours.
ClearanceNot Available
ToxicityInformation on acute overdosage with cilostazol in humans is limited. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias. The oral LD50 of cilostazol is >5.0 g/kg in mice and rats and >2.0 g/kg in dogs.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cilostazol Action PathwayDrug actionSMP00263
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9909
Caco-2 permeable-0.5666
P-glycoprotein substrateNon-substrate0.5361
P-glycoprotein inhibitor IInhibitor0.7886
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.5794
CYP450 2C9 substrateNon-substrate0.7887
CYP450 2D6 substrateNon-substrate0.7734
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9486
Ames testNon AMES toxic0.5436
CarcinogenicityNon-carcinogens0.9085
BiodegradationNot ready biodegradable0.9636
Rat acute toxicity1.9002 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7518
hERG inhibition (predictor II)Non-inhibitor0.7075
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral50 mg/1
Prices
Unit descriptionCostUnit
Pletal 100 mg tablet2.51USD tablet
Pletal 50 mg tablet2.39USD tablet
Cilostazol 100 mg tablet1.86USD tablet
Cilostazol 50 mg tablet1.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point160 °CPhysProp
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP3.38ALOGPS
logP3.31ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)14.42ChemAxon
pKa (Strongest Basic)-0.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area81.93 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.13 m3·mol-1ChemAxon
Polarizability41.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marioara Mendelovici, “Processes for preparing cilostazol.” U.S. Patent US20020099213, issued July 25, 2002.

US20020099213
General ReferencesNot Available
External Links
ATC CodesB01AC23
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (35.9 KB)
Interactions
Drug Interactions
Drug
AbciximabCilostazol may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Cilostazol can be increased when it is combined with Abiraterone.
AcenocoumarolCilostazol may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cilostazol.
AlprostadilAlprostadil may increase the anticoagulant activities of Cilostazol.
AlprostadilCilostazol may increase the antiplatelet activities of Alprostadil.
AlteplaseCilostazol may increase the anticoagulant activities of Alteplase.
ALX-0081Cilostazol may increase the anticoagulant activities of ALX-0081.
AminophenazoneThe serum concentration of Cilostazol can be increased when it is combined with Aminophenazone.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Cilostazol.
AmiodaroneThe metabolism of Cilostazol can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Cilostazol can be increased when it is combined with Amitriptyline.
AmprenavirThe serum concentration of Cilostazol can be increased when it is combined with Amprenavir.
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Cilostazol.
AnagrelideCilostazol may increase the anticoagulant activities of Anagrelide.
AncrodCilostazol may increase the anticoagulant activities of Ancrod.
AnistreplaseCilostazol may increase the anticoagulant activities of Anistreplase.
AntipyrineThe serum concentration of Cilostazol can be increased when it is combined with Antipyrine.
Antithrombin III humanCilostazol may increase the anticoagulant activities of Antithrombin III human.
ApixabanCilostazol may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Cilostazol can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Cilostazol can be decreased when used in combination with Aprotinin.
ArdeparinCilostazol may increase the anticoagulant activities of Ardeparin.
ArgatrobanCilostazol may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cilostazol.
ArmodafinilThe metabolism of Cilostazol can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Cilostazol can be decreased when combined with Artemether.
AstaxanthinCilostazol may increase the anticoagulant activities of Astaxanthin.
AtazanavirThe serum concentration of Cilostazol can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Cilostazol can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Cilostazol can be increased when it is combined with Atorvastatin.
AzelastineAzelastine may increase the anticoagulant activities of Cilostazol.
AzelastineCilostazol may increase the antiplatelet activities of Azelastine.
AzithromycinThe metabolism of Cilostazol can be decreased when combined with Azithromycin.
BatroxobinCilostazol may increase the anticoagulant activities of Batroxobin.
BecaplerminCilostazol may increase the anticoagulant activities of Becaplermin.
BemiparinCilostazol may increase the anticoagulant activities of Bemiparin.
BeraprostCilostazol may increase the anticoagulant activities of Beraprost.
BetaxololThe metabolism of Cilostazol can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Cilostazol can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Cilostazol can be increased when it is combined with Bicalutamide.
BifonazoleThe serum concentration of Cilostazol can be increased when it is combined with Bifonazole.
BivalirudinCilostazol may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Cilostazol can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Cilostazol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cilostazol can be decreased when it is combined with Bosentan.
BuprenorphineThe serum concentration of Cilostazol can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Cilostazol can be decreased when combined with Bupropion.
CaffeineThe metabolism of Cilostazol can be decreased when combined with Caffeine.
CangrelorCilostazol may increase the anticoagulant activities of Cangrelor.
CarbamazepineThe serum concentration of Cilostazol can be increased when it is combined with Carbamazepine.
CelecoxibThe metabolism of Cilostazol can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Cilostazol can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cilostazol can be increased when it is combined with Cerivastatin.
CertoparinCilostazol may increase the anticoagulant activities of Certoparin.
ChloramphenicolThe serum concentration of Cilostazol can be increased when it is combined with Chloramphenicol.
ChloroquineThe metabolism of Cilostazol can be decreased when combined with Chloroquine.
ChlorpromazineThe metabolism of Cilostazol can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Cilostazol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Cilostazol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cilostazol can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Cilostazol can be decreased when combined with Citalopram.
Citric AcidCilostazol may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Cilostazol can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Cilostazol can be decreased when combined with Clemastine.
ClevidipineThe serum concentration of Cilostazol can be increased when it is combined with Clevidipine.
ClobazamThe metabolism of Cilostazol can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Cilostazol can be decreased when combined with Clomipramine.
ClopidogrelClopidogrel may increase the anticoagulant activities of Cilostazol.
ClotrimazoleThe metabolism of Cilostazol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Cilostazol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Cilostazol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Cilostazol can be decreased when combined with Cocaine.
CollagenaseThe risk or severity of adverse effects can be increased when Cilostazol is combined with Collagenase.
ConivaptanThe serum concentration of Cilostazol can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Cilostazol can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Cilostazol can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Cilostazol can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateCilostazol may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Cilostazol can be decreased when it is combined with Dabrafenib.
DalteparinCilostazol may increase the anticoagulant activities of Dalteparin.
DanaparoidCilostazol may increase the anticoagulant activities of Danaparoid.
DarifenacinThe metabolism of Cilostazol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Cilostazol can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Cilostazol.
DeferasiroxThe serum concentration of Cilostazol can be decreased when it is combined with Deferasirox.
DefibrotideCilostazol may increase the anticoagulant activities of Defibrotide.
DelavirdineThe metabolism of Cilostazol can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Cilostazol is combined with Deoxycholic Acid.
DesipramineThe metabolism of Cilostazol can be decreased when combined with Desipramine.
DesirudinCilostazol may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Cilostazol can be increased when it is combined with Desloratadine.
DesmoteplaseCilostazol may increase the anticoagulant activities of Desmoteplase.
DexamethasoneThe serum concentration of Cilostazol can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe serum concentration of Cilostazol can be increased when it is combined with Dexfenfluramine.
DextranCilostazol may increase the anticoagulant activities of Dextran.
Dextran 40Cilostazol may increase the anticoagulant activities of Dextran 40.
Dextran 70Cilostazol may increase the anticoagulant activities of Dextran 70.
Dextran 75Cilostazol may increase the anticoagulant activities of Dextran 75.
DiazepamThe serum concentration of Cilostazol can be increased when it is combined with Diazepam.
DicoumarolCilostazol may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cilostazol.
DihydroergotamineThe metabolism of Cilostazol can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Cilostazol can be decreased when combined with Diltiazem.
Dimethyl sulfoxideThe serum concentration of Cilostazol can be increased when it is combined with Dimethyl sulfoxide.
DiphenhydramineThe metabolism of Cilostazol can be decreased when combined with Diphenhydramine.
DipyridamoleDipyridamole may increase the anticoagulant activities of Cilostazol.
DitazoleCilostazol may increase the anticoagulant activities of Ditazole.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cilostazol.
DoxycyclineThe metabolism of Cilostazol can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Cilostazol can be decreased when combined with Dronedarone.
Drotrecogin alfaCilostazol may increase the anticoagulant activities of Drotrecogin alfa.
DuloxetineThe metabolism of Cilostazol can be decreased when combined with Duloxetine.
Edetic AcidCilostazol may increase the anticoagulant activities of Edetic Acid.
EdoxabanCilostazol may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Cilostazol can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Cilostazol can be decreased when combined with Eliglustat.
EnoxaparinCilostazol may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Cilostazol can be decreased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Cilostazol.
EpinastineCilostazol may increase the antiplatelet activities of Epinastine.
EpoprostenolCilostazol may increase the anticoagulant activities of Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Cilostazol.
ErythromycinThe metabolism of Cilostazol can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Cilostazol can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Cilostazol can be decreased when combined with Esomeprazole.
EthanolThe serum concentration of Cilostazol can be increased when it is combined with Ethanol.
EthotoinThe serum concentration of Cilostazol can be increased when it is combined with Ethotoin.
Ethyl biscoumacetateCilostazol may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoricoxibThe serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.
EtravirineThe serum concentration of Cilostazol can be decreased when it is combined with Etravirine.
FelbamateThe serum concentration of Cilostazol can be increased when it is combined with Felbamate.
FibrinolysinCilostazol may increase the anticoagulant activities of Fibrinolysin.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cilostazol.
FluconazoleThe metabolism of Cilostazol can be decreased when combined with Fluconazole.
FluoxetineThe metabolism of Cilostazol can be decreased when combined with Fluoxetine.
FluvastatinThe serum concentration of Cilostazol can be increased when it is combined with Fluvastatin.
FluvoxamineThe metabolism of Cilostazol can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumCilostazol may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe metabolism of Cilostazol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cilostazol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Cilostazol can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Cilostazol can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Cilostazol can be increased when it is combined with Gefitinib.
GemfibrozilThe serum concentration of Cilostazol can be increased when it is combined with Gemfibrozil.
GliclazideThe serum concentration of Cilostazol can be increased when it is combined with Gliclazide.
GlucosamineGlucosamine may increase the antiplatelet activities of Cilostazol.
HaloperidolThe metabolism of Cilostazol can be decreased when combined with Haloperidol.
HeparinCilostazol may increase the anticoagulant activities of Heparin.
HirulogCilostazol may increase the anticoagulant activities of Hirulog.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cilostazol.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cilostazol.
IbudilastIbudilast may increase the anticoagulant activities of Cilostazol.
IbudilastCilostazol may increase the antiplatelet activities of Ibudilast.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Cilostazol.
Icosapent ethylCilostazol may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Cilostazol can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Cilostazol.
IfenprodilCilostazol may increase the antiplatelet activities of Ifenprodil.
IloprostIloprost may increase the anticoagulant activities of Cilostazol.
ImatinibThe metabolism of Cilostazol can be decreased when combined with Imatinib.
ImipramineThe metabolism of Cilostazol can be decreased when combined with Imipramine.
IndinavirThe metabolism of Cilostazol can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Cilostazol can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Cilostazol can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Cilostazol can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Cilostazol can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Cilostazol can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Cilostazol can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Cilostazol can be decreased when combined with Ketoconazole.
LansoprazoleThe serum concentration of Cilostazol can be increased when it is combined with Lansoprazole.
LepirudinCilostazol may increase the anticoagulant activities of Lepirudin.
LidocaineThe metabolism of Cilostazol can be decreased when combined with Lidocaine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Cilostazol.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cilostazol.
LopinavirThe serum concentration of Cilostazol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Cilostazol can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Cilostazol can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Cilostazol can be increased when it is combined with Losartan.
LovastatinThe metabolism of Cilostazol can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Cilostazol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Cilostazol can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Cilostazol can be decreased when combined with Lumefantrine.
MemantineThe serum concentration of Cilostazol can be increased when it is combined with Memantine.
MephenytoinThe serum concentration of Cilostazol can be increased when it is combined with Mephenytoin.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cilostazol.
MethadoneThe metabolism of Cilostazol can be decreased when combined with Methadone.
MethazolamideThe serum concentration of Cilostazol can be increased when it is combined with Methazolamide.
MethimazoleThe serum concentration of Cilostazol can be increased when it is combined with Methimazole.
MethotrimeprazineThe metabolism of Cilostazol can be decreased when combined with Methotrimeprazine.
MethsuximideThe serum concentration of Cilostazol can be increased when it is combined with Methsuximide.
MethylphenobarbitalThe serum concentration of Cilostazol can be increased when it is combined with Methylphenobarbital.
MetoprololThe metabolism of Cilostazol can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Cilostazol can be decreased when combined with Mexiletine.
MiconazoleThe serum concentration of Cilostazol can be increased when it is combined with Miconazole.
MifepristoneThe metabolism of Cilostazol can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Cilostazol.
MilrinoneCilostazol may increase the antiplatelet activities of Milrinone.
MirabegronThe metabolism of Cilostazol can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Cilostazol can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Cilostazol can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Cilostazol can be decreased when it is combined with Modafinil.
NadroparinCilostazol may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Cilostazol can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Cilostazol can be increased when it is combined with Naloxegol.
NCX 4016Cilostazol may increase the anticoagulant activities of NCX 4016.
NefazodoneThe serum concentration of Cilostazol can be increased when it is combined with Nefazodone.
NelfinavirThe metabolism of Cilostazol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Cilostazol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Cilostazol can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Cilostazol can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Cilostazol can be decreased when combined with Nilotinib.
NilutamideThe serum concentration of Cilostazol can be increased when it is combined with Nilutamide.
NilvadipineThe serum concentration of Cilostazol can be increased when it is combined with Nilvadipine.
NimesulideNimesulide may increase the anticoagulant activities of Cilostazol.
NimesulideCilostazol may increase the antiplatelet activities of Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cilostazol.
ObinutuzumabThe risk or severity of adverse effects can be increased when Cilostazol is combined with Obinutuzumab.
OlanzapineThe serum concentration of Cilostazol can be increased when it is combined with Olanzapine.
OlaparibThe metabolism of Cilostazol can be decreased when combined with Olaparib.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Cilostazol.
OmeprazoleThe metabolism of Cilostazol can be decreased when combined with Omeprazole.
OsimertinibThe serum concentration of Cilostazol can be increased when it is combined with Osimertinib.
OtamixabanCilostazol may increase the anticoagulant activities of Otamixaban.
OxcarbazepineThe serum concentration of Cilostazol can be increased when it is combined with Oxcarbazepine.
OxymetholoneThe serum concentration of Cilostazol can be increased when it is combined with Oxymetholone.
PalbociclibThe serum concentration of Cilostazol can be increased when it is combined with Palbociclib.
PanobinostatThe metabolism of Cilostazol can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Cilostazol can be decreased when combined with Pantoprazole.
ParnaparinCilostazol may increase the anticoagulant activities of Parnaparin.
ParoxetineThe metabolism of Cilostazol can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Cilostazol can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe serum concentration of Cilostazol can be increased when it is combined with Pegvisomant.
PentobarbitalThe metabolism of Cilostazol can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cilostazol.
Pentosan PolysulfateCilostazol may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Cilostazol.
PhenelzineThe serum concentration of Cilostazol can be increased when it is combined with Phenelzine.
PhenindioneCilostazol may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Cilostazol can be increased when combined with Phenobarbital.
PhenprocoumonCilostazol may increase the anticoagulant activities of Phenprocoumon.
PhensuximideThe serum concentration of Cilostazol can be increased when it is combined with Phensuximide.
PhenytoinThe metabolism of Cilostazol can be increased when combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cilostazol.
PioglitazoneThe serum concentration of Cilostazol can be increased when it is combined with Pioglitazone.
PlasminCilostazol may increase the anticoagulant activities of Plasmin.
PosaconazoleThe serum concentration of Cilostazol can be increased when it is combined with Posaconazole.
PrasugrelCilostazol may increase the anticoagulant activities of Prasugrel.
PrimidoneThe metabolism of Cilostazol can be increased when combined with Primidone.
ProbenecidThe serum concentration of Cilostazol can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Cilostazol can be increased when it is combined with Progesterone.
PromazineThe metabolism of Cilostazol can be decreased when combined with Promazine.
Protein CCilostazol may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeCilostazol may increase the anticoagulant activities of Protocatechualdehyde.
QuinidineThe metabolism of Cilostazol can be decreased when combined with Quinidine.
QuinineThe metabolism of Cilostazol can be decreased when combined with Quinine.
RabeprazoleThe serum concentration of Cilostazol can be increased when it is combined with Rabeprazole.
RanolazineThe metabolism of Cilostazol can be decreased when combined with Ranolazine.
RegorafenibThe serum concentration of Cilostazol can be increased when it is combined with Regorafenib.
ResveratrolResveratrol may increase the anticoagulant activities of Cilostazol.
ResveratrolCilostazol may increase the antiplatelet activities of Resveratrol.
ReteplaseCilostazol may increase the anticoagulant activities of Reteplase.
ReviparinCilostazol may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Cilostazol.
RidogrelCilostazol may increase the antiplatelet activities of Ridogrel.
RifabutinThe metabolism of Cilostazol can be increased when combined with Rifabutin.
RifampicinThe metabolism of Cilostazol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Cilostazol can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Cilostazol can be increased when it is combined with Rilpivirine.
RiociguatCilostazol may increase the hypotensive activities of Riociguat.
RitonavirThe serum concentration of Cilostazol can be increased when it is combined with Ritonavir.
RivaroxabanCilostazol may increase the anticoagulant activities of Rivaroxaban.
RolapitantThe metabolism of Cilostazol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Cilostazol can be decreased when combined with Ropinirole.
RosiglitazoneThe serum concentration of Cilostazol can be increased when it is combined with Rosiglitazone.
RosiglitazoneCilostazol may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cilostazol.
SaquinavirThe serum concentration of Cilostazol can be increased when it is combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Cilostazol.
SCH-530348Cilostazol may increase the antiplatelet activities of SCH-530348.
SelexipagCilostazol may increase the anticoagulant activities of Selexipag.
SeratrodastThe serum concentration of Cilostazol can be increased when it is combined with Seratrodast.
SertralineThe metabolism of Cilostazol can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the anticoagulant activities of Cilostazol.
SevofluraneCilostazol may increase the antiplatelet activities of Sevoflurane.
SildenafilThe metabolism of Cilostazol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Cilostazol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cilostazol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Cilostazol can be increased when it is combined with Simvastatin.
SitaxentanThe serum concentration of Cilostazol can be increased when it is combined with Sitaxentan.
SorafenibThe serum concentration of Cilostazol can be increased when it is combined with Sorafenib.
SRT501SRT501 may increase the anticoagulant activities of Cilostazol.
SRT501Cilostazol may increase the antiplatelet activities of SRT501.
St. John's WortThe serum concentration of Cilostazol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Cilostazol can be increased when it is combined with Stiripentol.
StreptokinaseCilostazol may increase the anticoagulant activities of Streptokinase.
SulfanilamideThe serum concentration of Cilostazol can be increased when it is combined with Sulfanilamide.
SulfisoxazoleThe metabolism of Cilostazol can be decreased when combined with Sulfisoxazole.
SulodexideCilostazol may increase the anticoagulant activities of Sulodexide.
TelaprevirThe serum concentration of Cilostazol can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Cilostazol can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Cilostazol can be increased when it is combined with Telmisartan.
TenecteplaseCilostazol may increase the anticoagulant activities of Tenecteplase.
TenofovirThe metabolism of Cilostazol can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Cilostazol can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Cilostazol can be decreased when it is combined with Teriflunomide.
TesmilifeneTesmilifene may increase the anticoagulant activities of Cilostazol.
TesmilifeneCilostazol may increase the antiplatelet activities of Tesmilifene.
ThalidomideThe serum concentration of Cilostazol can be increased when it is combined with Thalidomide.
TheophyllineThe metabolism of Cilostazol can be decreased when combined with Theophylline.
ThioridazineThe metabolism of Cilostazol can be decreased when combined with Thioridazine.
TicagrelorCilostazol may increase the anticoagulant activities of Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Cilostazol.
TinzaparinCilostazol may increase the anticoagulant activities of Tinzaparin.
TioconazoleThe serum concentration of Cilostazol can be increased when it is combined with Tioconazole.
TipranavirTipranavir may increase the antiplatelet activities of Cilostazol.
TirofibanTirofiban may increase the anticoagulant activities of Cilostazol.
TocilizumabThe serum concentration of Cilostazol can be decreased when it is combined with Tocilizumab.
TopiramateThe metabolism of Cilostazol can be decreased when combined with Topiramate.
TorasemideThe serum concentration of Cilostazol can be increased when it is combined with Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Cilostazol.
TranilastCilostazol may increase the antiplatelet activities of Tranilast.
TranylcypromineThe metabolism of Cilostazol can be decreased when combined with Tranylcypromine.
TrapidilTrapidil may increase the anticoagulant activities of Cilostazol.
TrapidilCilostazol may increase the antiplatelet activities of Trapidil.
TreprostinilCilostazol may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Cilostazol.
TriflusalCilostazol may increase the anticoagulant activities of Triflusal.
TroglitazoneThe serum concentration of Cilostazol can be increased when it is combined with Troglitazone.
TroleandomycinThe serum concentration of Cilostazol can be increased when it is combined with Troleandomycin.
UrokinaseCilostazol may increase the anticoagulant activities of Urokinase.
ValdecoxibThe serum concentration of Cilostazol can be increased when it is combined with Valdecoxib.
Valproic AcidThe serum concentration of Cilostazol can be increased when it is combined with Valproic Acid.
VemurafenibThe serum concentration of Cilostazol can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Cilostazol can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Cilostazol can be decreased when combined with Verapamil.
VismodegibThe serum concentration of Cilostazol can be increased when it is combined with Vismodegib.
Vitamin EVitamin E may increase the antiplatelet activities of Cilostazol.
VorapaxarCilostazol may increase the anticoagulant activities of Vorapaxar.
VoriconazoleThe metabolism of Cilostazol can be decreased when combined with Voriconazole.
WarfarinThe serum concentration of Cilostazol can be increased when it is combined with Warfarin.
WarfarinCilostazol may increase the anticoagulant activities of Warfarin.
XimelagatranCilostazol may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe serum concentration of Cilostazol can be increased when it is combined with Zafirlukast.
ZiprasidoneThe metabolism of Cilostazol can be decreased when combined with Ziprasidone.
ZonisamideThe serum concentration of Cilostazol can be increased when it is combined with Zonisamide.
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can significantly increase serum levels of this product.
  • Take on an empty stomach, a lipid rich meal will increase absorption.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
Gene Name:
PDE3A
Uniprot ID:
Q14432
Molecular Weight:
124978.06 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hong KW, Lee JH, Kima KY, Park SY, Lee WS: Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des. 2006;12(5):565-73. [PubMed:16472148 ]
  3. Schror K: The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9. [PubMed:12180353 ]
  4. Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z: Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol. 2008 Dec;59 Suppl 6:473-82. [PubMed:19218671 ]
  5. Parkkonen J, Hasala H, Moilanen E, Giembycz MA, Kankaanranta H: Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol. Pulm Pharmacol Ther. 2008;21(3):499-506. doi: 10.1016/j.pupt.2007.11.003. Epub 2007 Nov 22. [PubMed:18282775 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. [PubMed:10702888 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23